Allocell (implanted autologous skeletal myoblasts ) / U.S. Stem Cell - LARVOL DELTA

Massive β1-Adrenergic Receptor Reaction Explains Irreversible Acute Arrhythmia in a Fatal Case of Acute Pure Caffeine Intoxication. (PubMed, Cardiovasc Toxicol) - "Quantitation of catecholamines and their metabolites in urine samples was performed and showed level near the highest limit of normal ranges for norepinephrine and high level of epinephrine. Contraction band is a pathological modification of the myocell caused by the catecholaminergic action and can occur in conditions of alteration due to the interaction between calcium and catecholamines. We demonstrated the β1-adrenoceptor involvement in our fatal case by immunohistochemical analysis."

Clinical • Journal • Atrial Fibrillation • Cardiovascular

[VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (DGHO 2020) - "She received CMV prophylaxis with letermovir starting from d+14 on. On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • IFNG

[VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (DGHO 2020) - "She received CMV prophylaxis with letermovir starting from d+14 on. On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • IFNG

[VIRTUAL] Treatment of a patient with severe CMV reactivation after allo-HSCT with CMV-specific T cells from an external donor after failure of conventional antiviral therapy (DGHO 2020) - "She received CMV prophylaxis with letermovir starting from d+14 on. On d+65, the patient developed steroid-refractory grade III GvHD, mainly of the gut, which improved with the start of ruxolitinib...We treated her with ganciclovir and, for lack of response, with foscarnet without sufficient response... Adoptive CMV-specific T cell transfer from unrelated third-party donors is a feasible and effective method for the treatment of resistant CMV-viremia after allo-HSCT in patients with an inadequate response to regular treatment."

Clinical • Acute Myelogenous Leukemia • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation • IFNG

VIRUS-SPECIFIC T CELLS FROM STEM CELL, FAMILY AND THIRD PARTY T CELL DONORS: PATIENT MONITORING, DONOR SELECTION AND GMP-COMPLIANT MANUFACTURING (EBMT 2018) - "...The efficacy and the clinical outcome in high risk patients can be improved by a rapid recruitment of a suitable T-cell donor and an established method for fast manufacturing of antiviral T cells.To facilitate and accelerate donor recruitment a registry (alloCELL) for unrelated donors was established...Success of antiviral T-cell transfer benefits from(i) accurate monitoring of viral load and antiviral T-cell frequencies in patients,(ii) early and fast selection of suitable T-cell donors. Our data support clinical safety and efficacy of third-party antiviral T cells."

Clinical • Biosimilar • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease